Genprex Inc 2026年季度报告

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (Mark One)☒ For the quarterly period endedMarch 31, 2026or☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-38244 GENPREX, INC.(Exact name of registrant as specified in its charter) (512) 537-7997(Registrant’s telephone number, including area code) Securities registered pursuant to Section12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filingrequirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronicallyevery Interactive Data File required to be submitted pursuant to Rule 405 ofRegulation S-T(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit suchfiles). Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. Large accelerated filer☐Non-accelerated filer☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of May 11,2026, the registrant had 10,586,402shares of common stock, par value $0.001per share, outstanding. GENPREX, INC.FORM 10-Q TABLE OF CONTENTS ITEM 1.FINANCIAL STATEMENTSCondensed Consolidated Balance Sheets as of March 31, 2026(unaudited) and December 31, 2025Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2026and 2025(unaudited)Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three Months Ended March 31, 2026 and2025 (unaudited)Condensed Consolidated Statements of Cash Flows for the ThreeMonths Ended March 31, 2026and 2025(unaudited)Notes to Unaudited Condensed Consolidated Financial StatementsITEM 2.MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONSITEM 3.QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKITEM 4.CONTROLS AND PROCEDURES PART IIOTHER INFORMATION ITEM 1.LEGAL PROCEEDINGSITEM 1A.RISK FACTORSITEM 2.UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDSITEM 3.DEFAULTS UPON SENIOR SECURITIESITEM 4.MINE SAFETY DISCLOSURESITEM 5.OTHER INFORMATIONITEM 6.EXHIBITSSIGNATURES Genprex, Inc. CondensedConsolidated Balance Sheets Genprex, Inc. CondensedConsolidated Statements of Operations (unaudited) Genprex, Inc. Genprex, Inc. Condensed Consolidated Statements of Cash Flows (unaudited) Three Months Ended March 31,20262025Cash flows from operating activities:Net loss$(4,461,895)$(3,964,601)Adjustments to reconcile net loss to net cash used in operating activities:Share-based compensation and issuance of stock for services73,432184,199Changes in operating assets and liabilities:Prepaid expenses and other(227,877)(219,593)Research and development supplies299,020200,910Accounts payable911,959451,389Other current liabilities266,904(813,728)Net cash used in operating activities(3,138,457)(4,161,424)Cash flows from financing activities:Net proceeds from issuances of common stock13,356,8576,028,102Net cash provided by financing activities13,356,8576,028,102Net increase in cash and cash equivalents10,218,4001,866,678Cash and cash equivalents, beginning of period7,830,8551,601,660Cash and cash equivalents, end of period$18,049,255$3,468,338 GENPREX, INC.NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTSMARCH 31, 2026 Note 1- Description of Business and Basis of Presentation Unless the context requires otherwise, references to “Genprex,” the “Company,”“we,” “us” or“our” in this Quarterly Report on Form 10-Q refer toGenprex, Inc.Genprex, incorporated in Delaware in April 2008, is a clinical stage gene therapy company pioneering the development of gene-basedtherapies for large patient populations with unmet medical needs. The Company’s oncology platform utilizes its systemic, non-viral ONCOPREX®Delivery System which uses lipid-based nanoparticles in a lipoplex form to deliver tumor suppressor gene-expressing plasmids to cancer cells.Theproduct is administered intravenously, where it is taken up by tumor cells that then express tumor